The Mesoblast Ltd (ASX: MSB) share price is having a very strong start to the month.
At the time of writing, the biotechnology companyâs shares are up almost 13% to $1.07.
Whys is this ASX All Ords biotech share rocketing higher?
Investors have been scrambling to buy the ASX biotechâs shares following the release of a positive regulatory update.
According to the release, the allogeneic cellular medicines developer has resubmitted to the U.S. Food and Drug Administration (FDA) its Biologics License Application (BLA) for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).
The company notes that the resubmission contains substantial new information as required by the FDA.
This includes new long-term survival data of children enrolled in the Phase 3 trial showing durability of treatment effect through at least four years and new data showing remestemcel-Lâs treatment benefit in high-risk disease activity and on survival in propensity-matched studies of children in the Phase 3 trial.
It also highlights that new data shows that the validated potency assay has low variability and can adequately demonstrate manufacturing consistency and reproducibility. The lack of consistency was a key issue that the FDA had previously brought up.
All in all, management appears hopeful that this will be enough to get remestemcel-L approved by the FDA this time around.
Mesoblastâs chief executive, Dr. Silviu Itescu, commented:
There is an urgent need for a therapy that improves the dismal survival outcome in children with SRaGVHD. Our team has worked tirelessly over the past two years to provide a comprehensive response to the FDA. We are grateful for the agencyâs active dialogue and constructive feedback that will ensure a high bar is met in terms of product consistency and predictability of clinical outcomes.
Pleasingly, shareholders wonât have too long to wait for a result. The resubmission will have a review period up to six months from filing upon acceptance by FDA.
The post Guess which ASX All Ords biotech share is rocketing 13% on FDA news appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now…
See The 5 Stocks
*Returns as of January 5 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/izfr4xt
Leave a Reply